Novo finds new way to sell diabetes drug in EU while 2nd shot in US


Novo Nordisk is hustling to get work done so that it can resubmit its blockbuster hopeful Tresiba, a diabetes drug, to the FDA next year with an eye on getting into the market by 2016, three years after the FDA squelched its plans with its initial denial. In the meantime, Novo is finding new ways to combo Tresiba up and sell it in Europe where it is approved.

Read the source article at Pharma News

About the Author

Leave a Reply